TUCSON, Ariz., March 3, 2015 /PRNewswire/ -- The eleventh annual Tucson Symposium will be held March 17-18, where more than 450 of the world's top research scientists, academics, oncologists and pathologists will gather to debate new findings, discuss evolving theories and learn about new outcomes in patient treatments that may significantly affect the practice of medicine.
Each year Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, sponsors the Tucson Symposium at the Hilton El Conquistador in Tucson, Arizona to provide a forum for thought leaders to share new scientific achievements in cancer research and medical practice. Dr. Dan Von Hoff from the Translational Genomics Research Institute will deliver the opening keynote address.
"The Tucson Symposium continues to draw the best scientific minds in the industry," says Ventana Founder and Chief Scientific Advisor Dr. Thomas Grogan. "We look forward to again creating a pioneering environment where scientific collaborators can discover new technologies and advancements in pathology and oncology that can improve patients' lives."
At this year's event, participants will explore the latest advancements in breast cancer biology and biomarkers, personalized healthcare, cancer genomics, immunotherapy and cancer heterogeneity and evolution – technologies that are transforming current healthcare practices.
"Year after year, Ventana has included its collaborators in scientific discussions. The forum is an excellent opportunity to exchange knowledge, experience and new ideas on an interdisciplinary level. The meeting has continued to strengthen the company's focus on innovation and enables an unparalleled intimate exchange among practitioners, researchers and industry," said Dr. Manfred Dietel, Medical Director of the Institute of Pathology, University Hospital Charite, Berlin, Germany.
For more information about the Symposium, please visit www.tucsonsymposium.com.
About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of companion diagnostics to identify the patients most likely to respond favorably to specific therapies.
Visit www.ventana.com to learn more.
© 2015 Ventana Medical Systems, Inc.
VENTANA and the VENTANA logo are trademarks of Roche.
All other trademarks are the property of their respective owners.
VMSI Media Relations
Head of Corporate Communications
e-mail: Jacquie Bucher
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-scientific-collaborators-to-explore-latest-pathology-and-oncology-advancements-at-tucson-symposium-300044129.html
SOURCE Ventana Medical Systems, Inc.